AEDs will be replaced by Cardiac Science
This article was originally published in The Silver Sheet
Cardiac Science will replace about 24,000 automated external defibrillators (AEDs) used by first responders and certain medical facilities under an updated recall plan. The firm announced July 19 that it reached an agreement with FDA to swap potentially dysfunctional AEDs used by police, fire and ambulance workers, as well as hospitals, medical clinics, assisted living facilities and dialysis centers. Cardiac Science issued the field correction for its Powerheart and CardioVive AEDs in November 2009 after discovering the devices may fail to deliver therapy during a resuscitation attempt. The recall - which was classified as Class I by FDA in March - also included AEDs manufactured by Cardiac Science for GE Healthcare and Japan-based Nihon Kohden
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.